{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T10:46:58Z","timestamp":1781347618584,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.intimp.2025.114386","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T21:22:37Z","timestamp":1741468957000},"page":"114386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Genetic evidence of methotrexate's protective role against Parkinson's disease: A Mendelian randomization and co-localization study"],"prefix":"10.1016","volume":"152","author":[{"given":"Fang-Shu","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Na","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Feng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.114386_bb0005","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0002-9343(85)90312-2","article-title":"Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations","volume":"79","author":"Weinstein","year":"1985","journal-title":"Am. J. Med."},{"key":"10.1016\/j.intimp.2025.114386_bb0010","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41422-020-0291-z","article-title":"Targeting immunometabolism as an anti-inflammatory strategy","volume":"30","author":"P\u00e5lsson-McDermott","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.intimp.2025.114386_bb0015","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.redox.2017.07.018","article-title":"Direct antioxidant properties of methotrexate: inhibition of malondialdehyde-acetaldehyde-protein adduct formation and superoxide scavenging","volume":"13","author":"Zimmerman","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.intimp.2025.114386_bb0020","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s43587-022-00293-x","article-title":"Immune system-wide Mendelian randomization and triangulation analyses support autoimmunity as a modifiable component in dementia-causing diseases","volume":"2","author":"Lindbohm","year":"2022","journal-title":"Nat. Aging"},{"key":"10.1016\/j.intimp.2025.114386_bb0025","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40120-024-00609-6","article-title":"Methotrexate and the risk of dementia: A two-sample Mendelian randomization study","volume":"13","author":"Ma","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.intimp.2025.114386_bb0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M19-3369","article-title":"Adverse effects of low-dose methotrexate: a randomized trial","volume":"172","author":"Solomon","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2025.114386_bb0035","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1158\/1535-7163.MCT-06-0001","article-title":"Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4-carboxamide riboside","volume":"5","author":"Beckers","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2025.114386_bb0040","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.3390\/ijms21103483","article-title":"Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers","volume":"21","author":"Ko\u017ami\u0144ski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.114386_bb0045","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40265-018-0898-2","article-title":"Role of methotrexate in the management of psoriatic arthritis","volume":"78","author":"Elmamoun","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2025.114386_bb0050","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/cncr.20152","article-title":"High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma","volume":"100","author":"Crews","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2025.114386_bb0055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.hemonc.2019.08.008","article-title":"High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: case series and review of the literature","volume":"12","author":"Kapke","year":"2019","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"10.1016\/j.intimp.2025.114386_bb0060","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaad.2018.06.064","article-title":"Methotrexate for alopecia areata: a systematic review and meta-analysis","volume":"80","author":"Phan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2025.114386_bb0065","unstructured":"acog practice bulletin no. 193.pdf."},{"key":"10.1016\/j.intimp.2025.114386_bb0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-pathmechdis-031521-034145","article-title":"Genetics and pathogenesis of Parkinson\u2019s syndrome","volume":"18","author":"Ye","year":"2023","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.intimp.2025.114386_bb0075","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The emerging evidence of the Parkinson pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.intimp.2025.114386_bb0080","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1007\/s10943-023-01913-5","article-title":"Spirituality and spiritual distress in Parkinson\u2019s disease caregivers: A scoping review","volume":"62","author":"Seshadri","year":"2023","journal-title":"J. Relig. Health"},{"key":"10.1016\/j.intimp.2025.114386_bb0085","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1212\/WNL.56.6.730","article-title":"Risk of dementia in Parkinson\u2019s disease: a community-based, prospective study","volume":"56","author":"Aarsland","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2025.114386_bb0090","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s10930-024-10187-z","article-title":"Methotrexate for drug repurposing as an anti-aggregatory agent to mercuric treated \u03b1-chymotrypsinogen-A","volume":"43","author":"Ansari","year":"2024","journal-title":"Protein J."},{"key":"10.1016\/j.intimp.2025.114386_bb0095","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-pathmechdis-031521-034145","article-title":"Genetics and pathogenesis of Parkinson\u2019s syndrome","volume":"18","author":"Ye","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.intimp.2025.114386_bb0100","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1681\/ASN.2016010098","article-title":"Mendelian randomization as an approach to assess causality using observational data","volume":"27","author":"Sekula","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.intimp.2025.114386_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004383","article-title":"Bayesian test for colocalisation between pairs of genetic association studies using summary statistics","volume":"10","author":"Giambartolomei","year":"2014","journal-title":"PLoS Genet."},{"key":"10.1016\/j.intimp.2025.114386_bb0110","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2025.114386_bb0115","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ajhg.2022.04.001","article-title":"Combining evidence from Mendelian randomization and colocalization: review and comparison of approaches","volume":"109","author":"Zuber","year":"2022","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.intimp.2025.114386_bb0120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41582-020-0344-4","article-title":"Parkinson disease and the immune system - associations, mechanisms and therapeutics","volume":"16","author":"Tan","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.intimp.2025.114386_bb0125","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2147\/CLEP.S381289","article-title":"Identification of drugs associated with lower risk of Parkinson\u2019s disease using a systematic screening approach in a nationwide nested case\u2013control study","volume":"14","author":"Koponen","year":"2022","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.intimp.2025.114386_bb0130","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3390\/cells9071687","article-title":"Inflammation in Parkinson\u2019s disease: mechanisms and therapeutic implications","volume":"9","author":"Pajares","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2025.114386_bb0135","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2025.114386_bb0140","doi-asserted-by":"crossref","first-page":"e1273","DOI":"10.1212\/WNL.0000000000013303","article-title":"Disease-modifying antirheumatic drugs and risk of Parkinson disease","volume":"98","author":"Paakinaho","year":"2022","journal-title":"Neurology"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925003765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925003765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T05:08:13Z","timestamp":1757912893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925003765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":28,"alternative-id":["S1567576925003765"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114386","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic evidence of methotrexate's protective role against Parkinson's disease: A Mendelian randomization and co-localization study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114386"}}